A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower110
- Sponsors Roche
- 05 Jul 2017 Planned End Date changed from 1 Aug 2020 to 23 Apr 2020.
- 05 Jul 2017 Planned primary completion date changed from 20 Aug 2020 to 17 Jan 2019.
- 16 Jun 2017 Planned number of patients changed from 570 to 555.